Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01541332
Recruitment Status : Unknown
Verified March 2016 by Oncotherapeutics.
Recruitment status was:  Active, not recruiting
First Posted : February 29, 2012
Last Update Posted : March 10, 2016
Celgene Corporation
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2016
  Estimated Study Completion Date : December 2016